Kaposi's Sarcoma (KS) is the most common oral malignancy of AIDS patients and causes significant morbidity and mortality. The main tumor cell of KS is the spindle cell, a cell of endothelial origin. The etiologic agent of KS is Kaposi's Sarcoma-associated herpesvirus (KSHV) and is found in the spindle cells of all KS tumors. This proposal seeks to understand how latent KSHV activates endothelial cells through angiogenic and lymphangiogenic pathways to induce KS tumors in the oral environment. Latent KSHV infection increases the expression of both angiogenic and lymphangiogenic receptors in endothelial cells and this proposal will examine how KSHV activates both angiogenic and lymphangiogenic phenotypes. Integrins play a critical role in angiogenesis and in the first Aim, the role of KSHV induced integrins in the induction of angiogenic phenotypes during latency will be examined. A number of integrin inhibitors are in clinical trials and these studies will determine the potential of these inhibitors for treatment of KS tumors. KSHV also induces the differentiation of blood endothelial cells to lymphatic endothelial cells. Spindle cells in the KS tumor express markers of lymphatic endothelium and in particular VEGF receptor3 a key receptor in the induction of lymphangiogenesis.
In Aim 2 the mechanism of KSHV induced blood to lymphatic endothelial cell differentiation will be examined and new factors involved in this process will be analyzed to determine the mechanism of KSHV induced reprogramming to lymphatic endothelium. Finally, in Aim 3 we will determine if the integrins described in Aim 1 are highly expressed in oral KS tumors. The expression of previously undefined cellular factors critical for KSHV induced blood to lymphatic endothelial cell differentiation will also be examined in KS tissue. KSHV induces both angiogenic and lymphangiogenic receptors and phenotypes and a better understanding of how KSHV activates endothelial cells through these pathways will lead to new and better treatment options for KSHV and KS tumors.
Kaposi's Sarcoma is the most common oral tumor of AIDS patients. Kaposi's Sarcoma-associated herpesvirus (KSHV) is the infectious cause of KS. This proposal will lead to a better understanding of how KSHV activates tumor cells to cause KS and will lead to the use of new and better treatment strategies.
|Garrigues, H Jacques; DeMaster, Laura K; Rubinchikova, Yelena E et al. (2014) KSHV attachment and entry are dependent on ?V?3 integrin localized to specific cell surface microdomains and do not correlate with the presence of heparan sulfate. Virology 464-465:118-33|
|Fontaine, Krystal A; Camarda, Roman; Lagunoff, Michael (2014) Vaccinia virus requires glutamine but not glucose for efficient replication. J Virol 88:4366-74|
|Garrigues, H Jacques; Rubinchikova, Yelena E; Rose, Timothy M (2014) KSHV cell attachment sites revealed by ultra sensitive tyramide signal amplification (TSA) localize to membrane microdomains that are up-regulated on mitotic cells. Virology 452-453:75-85|
|Gutierrez, Kimberley D; Morris, Valerie A; Wu, David et al. (2013) Ets-1 is required for the activation of VEGFR3 during latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol 87:6758-68|
|Morris, Valerie A; Punjabi, Almira S; Wells, Robert C et al. (2012) The KSHV viral IL-6 homolog is sufficient to induce blood to lymphatic endothelial cell differentiation. Virology 428:112-20|
|DiMaio, Terri A; Gutierrez, Kimberley D; Lagunoff, Michael (2011) Latent KSHV infection of endothelial cells induces integrin beta3 to activate angiogenic phenotypes. PLoS Pathog 7:e1002424|